OKYO Pharma Limited - PDMR Dealing
09 juin 2022 02h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and...
OKYO Pharma Limited - PDMR Dealing
20 mai 2022 02h00 HE
|
OKYO Pharma LTD
LONDON and BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a life sciences company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing
19 mai 2022 16h00 HE
|
OKYO Pharma LTD
LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a life sciences company focused on the discovery and development of novel...
OKYO Pharma Limited - PDMR Dealing
18 mai 2022 06h35 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation
17 mai 2022 02h00 HE
|
OKYO Pharma LTD
LONDON, May 17, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), a life sciences company focused on the discovery and development of novel molecules...
OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing
16 mai 2022 18h12 HE
|
OKYO Pharma LTD
LONDON, May 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused on the discovery and development of novel...
OKYO Pharma ("OKYO" or the "Company") - Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
27 avr. 2022 02h00 HE
|
OKYO Pharma LTD
OK-101 ameliorates neuropathic corneal pain in a mouse model of ciliary nerve ligation BAM8-22 peptide analog OK-201 alleviates neuropathic corneal pain in mice LONDON, April 27, 2022 (GLOBE...
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC for a proposed dual-listing on the Nasdaq Capital Market and Offering in the United States
07 mars 2022 02h00 HE
|
OKYO Pharma LTD
LONDON, March 07, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) ("OKYO" or the "Company"), a biotechnology company focused on the discovery and development of novel...
OKYO Pharma ("OKYO" or the "Company") - announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain
23 févr. 2022 02h00 HE
|
OKYO Pharma LTD
LONDON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry...
OKYO Pharma Limited ("OKYO" or the "Company") - Conversion of CLNs, cashless exercise of Warrants, and issue of equity
21 févr. 2022 12h00 HE
|
OKYO Pharma LTD
LONDON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry...